Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 10/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 10/20 | 0.59 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.59 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.58 |
| ▸ | PARP1 | P09874 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30186048 | 1.00 | TNKS (0.59) | TNKSTNKS2PARP2PARP14PARP1 | |
| SCHEMBL17298078 | 0.87 | TNKS2 (0.60) | TNKSTNKS2PARP2PARP14PARP1 | |
| SCHEMBL19104690 | 0.83 | TNKS (0.56) | TNKSTNKS2PARP2PARP14PARP1 | |
| SCHEMBL3980805 | 0.82 | TNKS (0.65) | TNKSTNKS2PARP2PARP14PARP1 | |
| SCHEMBL3423314 | 0.81 | TNKS (0.67) | TNKSTNKS2PARP2PARP14PARP1 | |
| SCHEMBL6929158 | 0.81 | PARP1 (0.64) | TNKSTNKS2PARP2PARP14PARP1 | |
| SCHEMBL31483817 | 0.81 | PARP1 (0.64) | TNKSTNKS2PARP2PARP14PARP1 | |
| SCHEMBL7696287 | 0.80 | TNKS (0.62) | TNKSTNKS2PARP2PARP14PARP1 | |
| SCHEMBL21127496 | 0.79 | PARP14 (0.60) | TNKSTNKS2PARP2PARP14PARP1 | |
| SCHEMBL4063142 | 0.79 | SMN1; SMN2 (0.50) | PARP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| EP-4212515-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-4212515-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3728207-B1 | QUINAZOLINONES AS PARP14 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-3728207-B1 | QUINAZOLINONES AS PARP14 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20230018702-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2023-01-19 | — | — | US | disclosed |
| US-20230018702-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2023-01-19 | — | — | US | disclosed |
| US-11008308-B2 | Quinazolinones as PARP14 inhibitors | Ribon Therapeutics Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008308-B2 | Quinazolinones as PARP14 inhibitors | Ribon Therapeutics Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200247788-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2020-08-06 | — | — | US | disclosed |
| US-20200247788-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2020-08-06 | — | — | US | disclosed |
| US-10562891-B2 | Quinazolinones as PARP14 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190194174-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2019-06-27 | — | — | US | disclosed |
| WO-2011012622-A1 | BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | TNKS 16/4885TNKS2 17/4885PARP2 10/4885 |
| US-20200247788-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | TNKS 16/4885TNKS2 17/4885PARP2 10/4885 |
| US-10562891-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | TNKS 16/4885TNKS2 17/4885PARP2 10/4885 |
| US-11008308-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | TNKS 16/4885TNKS2 17/4885PARP2 10/4885 |
| US-20230018702-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | TNKS 16/4885TNKS2 17/4885PARP2 10/4885 |
| US-20190194174-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | TNKS 16/4885TNKS2 17/4885PARP2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.